Yes; the market size for these eye afflictions is truly huge. And it's not as if PYC's treatment will need to take a share of it; if it doesn't have the downside of the VEGF inhibitor it should simply replace it (once doctors are educated as to what it can do.) I can only imagine the effect on the economy of people who would normally be blind and need care instead being able to care for themselves? It would be a big burden removed.
PYC Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)